Research Departments & Organizations
Discovery to Cure Internship
Dr. Kluger is a medical oncologist and the Associate Director for Education, Training and Faculty Development at Yale Cancer Center, as well as the Deputy Section Chief for Medical Oncology. She sees patients with melanoma and renal cell carcinoma. Approximately half of her time is spent conducting laboratory-based clinical and translational research. She runs an active laboratory focusing on melanoma-related studies, and has been an integral member of the Yale SPORE in Skin Cancer since it was initially awarded in 2006, having co-led four projects during this time. Dr. Kluger collaborates with basic and clinical scientists as evidenced by her funding and publication record. Her particular focus is on predictive biomarkers and development of novel therapies, both directly anti-neoplastic and immune activating. She has extensive experience in conducting correlative predictive and prognostic biomarker studies using a variety of technologies, including exome sequencing, expression arrays, tissue microarrays and others. Her lab conducts pre-clinical targeted drug testing and knock-down studies. She also has experience in designing and conducting clinical trials with laboratory correlates, including investigator initiated trials. All of these trials involve specimen collection (tumor and blood) and analysis. She has been very involved in development of single drug and combination checkpoint regimens, and is well versed with aspects of biomarker development for predicting response to this class of drugs.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. Clin Cancer Res. 2017 Aug 1;23(15):4270-4279 2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Br J Cancer. 2017 Feb 14;116(4):432-440 2017
Melanoma central nervous system metastases: current approaches, challenges, and opportunities.
Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642 2016
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM, Yu JB, Kluger HM, Chiang VL. Cancer. 2016 Oct;122(19):3051-8 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Lancet Oncol. 2016 Jul;17(7):976-983. 2016
Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism.
Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C, Desir GV. Cancer Res. 2016 Jul 1;76(13):3884-94 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. N Engl J Med. 2016 Jun 30;374(26):2542-52 2016
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.
Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM. Cancer Immunol Res. 2016 Mar;4(3):179-82 2016